Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tragacanth is a natural, complex anionic heteropolysaccharide obtained from the dried sap of several species of Middle Eastern legumes in the genus *Astragalus*, most notably *Astragalus gummifer*. It consists of two primary fractions: tragacanthin, which is water-soluble, and bassorin, which swells in water to form a gel. In the pharmaceutical industry, tragacanth is traditionally utilized as a thickening agent, emulsifier, and stabilizer. Modern biomedical research has expanded its utility to include its use as a bioadhesive matrix in 3D-printed patches for wound healing and liver bleeding, a scaffold material for bone tissue engineering, and a stabilizer for nanoparticle-based drug delivery systems. Its high viscosity at low concentrations and stability across a wide pH range make it an effective excipient for sustained-release oral formulations and topical hydrogels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tragacanth.